胶原交联治疗眼科疾病的进展  

Recent advancement of collagen cross-linking in the treatment of ophthalmic diseases

作　　者：莫利娟[1] 李青松[1] 张兴儒[1] 

机构地区：[1]上海中医药大学附属普陀医院眼科,200062

出　　处：《国际眼科纵览》2016年第4期241-246,共6页International Review of Ophthalmology

基　　金：普陀区自主创新重大课题（15-PT-01）

摘　　要：虽然胶原交联（collagencross—linking，CXL）技术在眼科还处于研究和试验性阶段，但因其能显著提高胶原纤维的机械强度，所以正在逐渐成为广大眼科医生关注的热点。近年来在传统角膜交联术的基础上，出现了高能量加速角膜交联、电离导入角膜交联以及联合治疗等方法，其在眼科疾病的应用所获得的经验大多来自于治疗圆锥角膜，一旦确认圆锥角膜处于进展期，可及早给予胶原交联治疗，术后角膜病情稳定，视力提高，而对于非进展期圆锥角膜的治疗有待进一步研究。另外，CXL在医源性圆锥角膜、透明边缘变性、角膜水肿和感染性角膜病变中也有了一些应用，具体效果有待进一步验证。Although collagen cross-linking （CXL） technology is still in the research and experimen- tal stage in ophthalmology, but which is likely to significantly improve the mechanical strength of the collagen fibers, so a great number of ophthalmologists are becoming concerned about it. In recent years, based on the traditional CXL, the high-energy accelerated CXL, iontophoresis CXL and combination procedures are being described, Most of the experience gained from the treatment of the keratoeonus. If individuals have been di- agnosed as progressive keratoconus, they can be given CXL treatment early. After the operation, patients ap- pear to increase the corneal stability and improve the visual acuity, while as to non-progression of keratoeo- nus, the efficacy of the CXL is still in need of further study. In addition, CXL were attempted to be applied on the treatment of the iatrogenie keratoconus, transparent marginal degeneration, cornea/edema and infec- tious corneal diseases, but the efficacy remains to be further verified.

关 键 词：胶原交联 眼科 

分 类 号：R77[医药卫生—眼科]